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Objective: To evaluate whether clinically significant anxiety is an
independent risk factor for dementia, taking into account both
depression among potentially confounding factors and the competing
risk of death.
Method: During the Zaragoza Dementia and Depression
(ZARADEMP) study, a random sample of community dwellers aged
55 years or older was assessed (n = 4803), and a two-wave, 4.5-year
follow-up was completed. Geriatric Mental State (GMS)-AGECAT
criteria were used to diagnose anxiety and DSM-IV criteria were
applied to diagnose incident dementia. The multivariate Fine and Gray
regression model was implemented to calculate dementia risk.
Results: Compared with non-cases (GMS-AGECAT criteria), the
incidence rate of dementia was significantly higher in subcases of
anxiety, and particularly significant in the cases of anxiety (incidence
rate ratio (IRR): 2.77; P = 0.010). Cases of anxiety, but not subcases, at
baseline were significantly associated with dementia risk (adjusted
subdistribution hazard ratio (SHR): 2.7; P = 0.019).
Conclusion: Clinically significant anxiety is associated with an almost
threefold increase in the risk of dementia in the population, even when
controlling for depression and considering mortality in the competing
risks model.
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Significant outcomes
• The incidence rate of dementia was almost 3-fold higher in cases of clinically significant anxiety com-
pared with non-cases.
• Clinically significant anxiety confers a 2.7-fold risk of dementia, even when controlling for depression
and using a competing risk model that minimizes the probability of overestimating the risk of disease
in the presence of high rates of mortality.
• The association between subcases of anxiety at baseline and dementia risk did not reach statistical
significance.
Limitations
• The attrition rate in the study limits the generalizability of results, although this was expected by
design.
• Data on ApoE-e4 were not obtained.
• We did not control for the use of psychotropic medications, which may be associated with a higher
risk of dementia.
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Introduction
The World Health Organization recognized
dementia as a public health priority in 2012 (1).
The burden of this condition is expected to
increase with societal aging over the coming years
(1), even though recent reports show that the age-
specific incidence of dementia may be declining (2).
In the absence of a disease-modifying treatment or
cure, risk reduction of dementia becomes especially
relevant. Modifiable risk factors include sedentary
lifestyle, diabetes, and cardiovascular disease (3),
but other neuropsychiatric symptoms such as
depression and anxiety may be important (4).
Several population studies have documented an
association between depression and dementia,
but the nature and extent of this association
remains unclear. Two meta-analyses suggest that
depression is a true risk factor for dementia (5, 6),
although other studies suggest that depression is
actually a prodromal symptom of diseases that
cause dementia (7).
The relationship between anxiety and dementia
has received recent attention (8–13), but the nature
of this relationship (true association or reverse
causation) remains unclear. The few studies of anx-
iety as a risk factor for dementia have produced
conflicting results. Several studies suggest that anx-
iety is a risk factor for dementia (8, 9, 14) while
three other investigations estimate that dementia
risk is increased by 48–70% in those with anxiety
symptoms (11–13). However, de Bruijn et al. (10)
found no association of either anxiety symptoms
or anxiety disorder. These inconsistencies may
reflect variations in factors such as the length of
observation, follow-up attrition rate, potentially
modifying variables controlled for, or method of
assessing either anxiety or dementia. With the
exception of de Bruijn et al. (10), who used DSM-
IV diagnostic criteria to identify anxiety disorder
in one sample, others used only scales and ques-
tionnaires (8, 10–13), and none used methods rec-
ommended specifically for use in the elderly (15).
Moreover, previous studies of anxiety and
dementia did not consider the competing risk of
death, which should probably be mandatory in risk
model estimates, particularly in the elderly, as
death may preclude the occurrence of dementia
(16).
Aims of the study
We evaluated whether clinically significant anxiety
is a risk factor for dementia in a community
sample, taking into account the competing risk of
death.
Methods
Sample
Data were obtained from the Zaragoza Dementia
and Depression (ZARADEMP) study, a 5-wave,
longitudinal community study carried out in
Zaragoza, Spain (17). We present data from baseline
(Wave I, starting in 1994) and from two follow-up
visits (Wave II, starting in 1997; andWave III, start-
ing in 1999). Briefly, in 1991 a random sample of
community-dwelling persons aged 55 years or older
was drawn proportionally by age and sex from the
census list of Zaragoza (Spain). Institutionalized
individuals were included. A total of 4803 subjects
underwent at baseline interview (Wave I). Because
we were interested in dementia-free individuals, 746
subjects identified as dementia cases or subcases
(i.e., those with suggestive but ambiguous symp-
toms) were not studied further, leaving a residual
sample of 4057 for follow-up studies.
The principles of the Declaration of Helsinki were
followed throughout. The Ethics Committee of the
University of Zaragoza, and the Fondo de Investi-
gacion Sanitaria (FIS) approved the study protocol,
according to Spanish Law. All individuals included
in the study provided written informed consent.
Procedure
A two-phase screening procedure was used at
baseline and in each subsequent wave. First (Phase
I), well-trained and regularly supervised lay inter-
viewers conducted the 25- to 90-min ZARADEMP
interview at the subjects’ home or place of residence.
The ZARADEMP interview incorporates validated
Spanish versions of several international
instruments. The Mini-Mental State Examination
(MMSE) (18, 19) screens cognitive function. The
Geriatric Mental State (GMS), a semistructured
standardized clinical interview, assesses the mental
state of elderly persons (20, 21), yielding data
suitable for the AGECAT computer system that
identifies psychiatric diagnoses (22). We also used
the History and Aetiology Schedule (HAS), a
standardized method of collecting history data from
a caregiver or directly from reliable respondents
(23). The Katz Index (24, 25) and the Lawton and
Brody Scale (26, 27) assessed basic and instrumental
activities of daily living. A series of questions regard-
ing medical and psychiatric history from the EURO-
DEM (European Community Concerted Action on
the Epidemiology and Prevention of Dementia)
Study Risk Factors Questionnaire was also pre-
sented (28).
Periodic re-training of interviewers was used to
avoid a decay in reliability. In phase II, trained
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supervising research psychiatrists reassessed those
individuals considered to be ‘probable psychiatric
cases’, and/or participants with information
considered to be unreliable. These interviews were
also conducted in the participants’ place of resi-
dence, and the same instruments were used. Our
previous studies support the validity of this case-
finding procedure (20).
Dementia assessment and diagnosis
Participants in the follow-up waves (Waves II and
III) were classified in phase I as ‘probable cases’ of
dementia based on the GMS threshold ‘global’
score (>1) and/or MMSE standard cut-off points
(<24). Those with a GMS ‘global score’ of 1 were
considered to be ‘sub-cases’. In phase II, all
probable cases of dementia were reassessed in their
place of residence by a research psychiatrist using
the same methods as well as the Hachinski’s scale
(29) and a brief, previously standardized neuro-
logic examination. Incident dementia was initially
diagnosed by the research psychiatrist doing the
assessment, but the final DSM-IV diagnosis, made
by consensus, required the agreement of at least
three psychiatrists in a four-member panel. Previ-
ous studies support the validity of this diagnostic
process (20). Moreover, to document the accuracy
of the panel, a proportion of cases were
invited to undergo a hospital-based diagnostic
work-up, which incorporated a neuropsychological
diagnostic battery and neuroimaging studies.
Agreement on the diagnosis of dementia was
reached in 95.8% of the cases.
Anxiety assessment and diagnosis
The staged GMS-AGECAT approach was applied
to diagnose anxiety at baseline. Although the
GMS does not map precisely onto the DSM or
ICD categories, it was calibrated to detect
disorders of clinical severity, and has been used in
several studies to describe anxiety disorders (30,
31). This diagnostic approach is valid in commu-
nity samples, and participants with AGECAT
scores of 3, 4, and 5 in the 0–5 scale are considered
to be likely ‘cases’ of anxiety (clinically significant
anxiety requiring clinical intervention); those with
scores of 1 and 2 are considered to be ‘sub-cases’
(mild anxiety), and those with a score of 0 are
considered to be ‘non-cases’ (unaffected) (32).
Covariates
Potentially confounding factors were assessed
at baseline, and included sociodemographic
characteristics (age, sex, educational level, marital
status, and living alone), medical risk factors
(vascular disease, hypertension, and diabetes),
health status, depression, and cognitive status.
Education was categorized into three levels:
‘illiterate’ (unable to read and write, and/or
<2 years of formal education), ‘primary’ (complete
or incomplete), and ‘secondary school or higher’.
Marital status was categorized as follows: ‘single’,
‘married or living as a couple’, ‘divorced or
separated’, and ‘widowed’. Health status was rated
according to the HAS criteria and dichotomized as
‘good (physical illness absent)’ or ‘not good
(physical illness present)’.
Blood pressure (BP) was measured during the
interview using a standard manual tensiometer,
using the mean of two BP readings; hypertension
was defined as BP >140/90 mmHg or receiving
treatment for hypertension. The presence of
vascular risk factors and diabetes was based on the
medical history obtained by using the EURODEM
Risk Factors Questionnaire (28). The presence of
vascular diseases was dichotomized, distinguishing
between vascular disease (angina, myocardial
infarct, and/or stroke) and no history of vascular
disease. Diabetes was dichotomized into persons
with a previous medical diagnosis or receiving
treatment for diabetes and the absence of diabetes.
The diagnosis of depression was based on the
AGECAT computer system (33).
Statistical analysis
Differences between baseline characteristics
according to anxiety status were assessed using
two-tailed chi-square tests on categorical data, and
differences in variables with approximately normal
distributions were assessed using analysis of
variance.
Standard procedures were used to calculate inci-
dence rate and incidence rate ratio (IRR). The fol-
low-up period ended at the second follow-up
examination (Wave III) for the non-demented indi-
viduals, at the date of invitation for refusals, at the
date of moving away or death (based on actual
data from the Civil Registry, ‘Padron Municipal
de Habitantes de Zaragoza’), or at the time of
onset of dementia for cases. The time of onset of
dementia was estimated to be the time from
baseline to the midpoint between diagnosis and the
previous examination.
We used a multivariate survival analysis with
age as a time-scale with delayed entry (34) to
study the specific hypothesis that anxiety disorder
is associated with an increased risk of overall
dementia. In a first step of the survival analysis,
3
Anxiety as a risk factor for dementia
we built the cumulative incidence functions (CIF)
(35) for the anxiety disorder groups to estimate
the probability of incident overall dementia taking
into account the competing event (death) as time
progressed (36–38). We tested for equality of CIF
across groups (39). Then, to estimate the
effect of baseline predictors on the cumulative
incidence function, we used the Fine and
Gray (36) regression model to estimate the
subdistribution hazard. This model modifies the
Cox proportional hazards model, allowing for
competing risks (death). To explore mechanisms
explaining the association, we used two models in
which we gradually controlled for potential
confounders and/or effects modifiers. Interactions
between covariates (sociodemographic characteris-
tics, medical risk factors, health status, depres-
sion, and cognitive status) and anxiety diagnosis
were assessed before calculating the multivariate
regression model, and no statistically significant
interactions were detected. To examine the
assumption of proportional distribution hazards,
we tested the time-varying effect of each covariate
using the Scheike and Zhang test (40). Statistical
analyses were conducted using R software (http://
www.r-project.org), with the epiR package to ana-
lyze epidemiologic data, and the cmprsk and time-
reg packages for survival analyses.
Stratified sample available 
from the last census data in 
1991 (N = 9739)
Deceased (18.9%)
Moved away (3.6%)
Refusal (20.5%)
Utraced (7.6%)
ZARADEMP I
Eligible sample
(N = 4803)
Included at baseline
(N = 4057)
Anxiety non-cases
(N = 2321)
Incident 
dementia 
cases
(N = 67)
Non-cases of 
dementia
(N = 1363)
Deceased (N = 396)
Moved away (N = 24)
Refusal (N = 153)
Untraced (N = 114)
Others (N = 204)
Anxiety subcases
(N = 1645)
Incident 
dementia 
cases
(N = 64)
Non-cases of 
dementia
(N = 930)
Deceased (N = 317)
Moved away (N = 15)
Refusal (N = 125)
Untraced (N = 82)
Others (N = 112)
Anxiety cases
(N = 91)
Incident 
dementia 
cases
(N = 7)
Non-cases of 
dementia
(N = 47)
Deceased (N = 17)
Moved away (N = 0)
Refusal (N = 5)
Untraced (N = 8)
Others (N = 7)
Excluded: Dementia, cases and 
subsyndromal
(N = 746)
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Fig. 1. Study flowchart. AGECAT, Automated Geriatric Examination for computer asisted taxonomy; ZARADEMP, Zaragoza
Dementia and Depression Project.
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Results
Figure 1 illustrates the flow diagram of the
ZARADEMP Project. The refusal rate for initial
examination was 20.5%, and 4803 individuals were
ultimately interviewed at baseline in 1994. Wave II
was completed in 1997, and wave III in 1999.
Between the wave I baseline and wave III, 730
(17.9%) individuals died, and 849 (20.9%) were
lost during follow-up, leaving an examined sample
of 2479 (61.1%) for wave III follow-up.
Those lost during follow-up were on average
4.3 years older (P < 0.001) and more likely to be
illiterate than those re-evaluated; the MMSE
scores were also lower among those lost
(P < 0.001). The lost and examined groups
had a similar sex distribution. At baseline, 91
participants (2.2%) were diagnosed with anxiety,
and 1645 (40.5%) were classified as subcases of
anxiety.
The baseline characteristics according to anxiety
status are displayed in Table 1. Compared with
non-cases, subcases of anxiety were more likely to
be female, illiterate, and to live alone; to perform
worse cognitively, and to have depression,
functional disabilities, and to be unhealthy with
diabetes and vascular disease. Compared with
non-cases, those who received anxiety diagnoses
were more likely to be female, to live alone, to
perform worse cognitively, to have depression and
disabilities for instrumental ADLs, and to be
unhealthy. Compared with subcases, cases of
anxiety were more likely to be female, to have
depression and disabilities for instrumental ADLs,
and to be unhealthy.
The median follow-up time was 4.4 years
(interquartile range: 3.0–4.9). At wave III, 138
(3.4%) participants were diagnosed as incident
cases of dementia (Fig. 1). Seven out of the 91
cases with clinically significant anxiety followed up
(amounting a total of 346 person-years follow-up)
developed dementia.
Table 2 shows the risk of overall dementia in
relation to the anxiety status. Compared with non-
cases, both the proportion of incident cases and
the incidence rate of dementia were higher among
subcases, and particularly higher among cases of
anxiety, the IRR being significantly higher among
the latter (IRR = 2.77; P = 0.010).
The incidence rate of dementia was higher
among cases of anxiety than in subcases, but this
differences did not reach statistical significance
(IRR = 1.98; P = 0.075).
Then, when the competing risk of mortality is
taken into account in the dementia risk calcula-
tion, crude comparison of the CIF by anxiety
status shows that in the 4.5-year follow-up, com-
pared with the non-cases, the probability of
developing dementia was higher in individuals with
anxiety, particularly in the anxiety cases (Fig. 2).
For example, for individuals aged 85 years, the
probability (in percentage) of dementia in the non-
cases group was 4.0% (95% confidence interval
[CI]: 2.7%–5.7%), significantly lower than in both
the subcases group (6.1%; 95% CI: 4.3%–8.5%)
and the cases group (8.7%; 95% CI: 2.6%–
19.6%).
Table 3 shows the results of the competing risk
regression analysis of incident dementia associated
with anxiety status. The univariate analysis
revealed a significant association between anxiety
cases at baseline and dementia risk, and this
association persisted in the fully adjusted model
Table 1. Baseline characteristics according to anxiety status
Anxiety
non-cases
(N = 2321)
Anxiety
subcases
(N = 1645)
Anxiety cases
(N = 91) P
Mean (SD) Mean (SD) Mean (SD)
Age (years) 72.0 (9.1) 72.2 (9.2) 72.3 (8.6) 0.538
MMSE 27.4 (2.6) 27.0 (2.4)* 26.4 (3.9)† <0.001
N (%) N (%) N (%)
Female sex 1063 (48.8%) 1096 (66.6%)* 70 (76.9%)†,‡ <0.001
Education 0.001
Illiterate 186 (8.0%) 152 (9.2%) 10 (11.0%)
Primary
school
1688 (72.7%) 1263 (76.7%) 68 (74.7%)
Secondary
school or
higher
447 (19.2%) 230 (13.9%)* 13 (14.3%)
Civil status 0.065
Married/
couple
1491 (64.4%) 981 (59.8%) 56 (61.5%)
Divorced/
separated
28 (1.2%) 28 (1.7%) 2 (2.2%)
Widowed 586 (25.3%) 481 (29.3%) 27 (29.7%)
Living alone 371 (16.0%) 306 (18.6%)* 24 (26.4%)† 0.007
Depression 68 (2.9%) 342 (20.8%)* 45 (49.5%)†,‡ <0.001
Disability
Instrumental
ADLs
245 (10.6%) 241 (14.7%)* 26 (28.9%)†,‡ <0.001
Basic ADLs 117 (5.1%) 155 (9.4%)* 5 (5.5%) <0.001
Health status
(‘not good’)
1084 (46.7%) 952 (58.0%)* 65 (71.4%)†,‡ <0.001
Vascular risk factors
Hypertension 1565 (67.5%) 1121 (68.3%) 61 (67.0%) 0.871
Diabetes 264 (11.4%) 223 (13.7%)* 14 (15.4%) 0.070
Vascular
disease
236 (10.2%) 211 (12.8%)* 12 (13.2%) 0.030
Data are given as mean (standard deviation) or number (%). ADLs, activities of daily
living; MMSE, Mini-Mental State Examination.
*Significant differences (P < 0.05) between ‘anxiety subcases’ and ‘anxiety non-
cases’ in either t (df = 3964) test or v2 (df = 1) test.
†Significant differences (P < 0.05) between ‘anxiety cases’ and ‘anxiety non-cases’
in either t (df = 2410) test or v2 (df = 1) test.
‡Significant differences (P < 0.05) between ‘anxiety cases’ and ‘anxiety subcases’
in either t (df = 1734) test or v2 (df = 1) test.
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with the inclusion of all potential confounding fac-
tors (Subdistribution Hazard Ratio [SHR] = 2.7;
P = 0.019). No significant association between sub-
cases of anxiety at baseline and dementia risk was
found in either model.
Discussion
This study shows that, compared with non-cases,
clinically significant anxiety increases the risk of
dementia almost three times, although the differ-
ence did not reach statistical significance in the
anxiety subcases. While some, but not all, of the
previous reports showing an association of
anxiety with incident dementia (8), also con-
trolled for depression, this is the first study in
which a competing risk model was used (41).
This is an advantage over traditional models
(e.g., Kaplan–Meier and Cox regression), which
do not take into account competing risks of
death and may overestimate the risk of disease in
the presence of high rates of mortality. This is
particularly important in studies of the elderly
(16). In support of this method, a secondary
analysis in this study demonstrated that, accord-
ing to the Kochar–Lam–Yip test (42), the risk of
death was significantly higher than the risk of
overall dementia (P < 0.001, data not shown).
Moreover, in controlling for the effect of age at
baseline in the risk of dementia, we, like Petkus
et al. (11), used exact age as the time-scale, in
contrast to previous studies using a time-on-
study and including age as a covariate in the
regression models (10, 12, 13). The exact age as
time-scale is preferred for avoiding a bias on
effect estimates in samples of older adults
because age is strongly associated with some
covariates (e.g., chronic diseases) (34). We have
previously documented in this same sample that
the dementia risk increases significantly with an
individual’s age (43).
Most recent reports documenting an association
between anxiety and all-cause dementia (8, 9,
11–13), such as the ones included in the systematic
review and meta-analysis of Gulpers et al. (14),
used questionnaires and scales in the assessment of
anxiety. However, Therrien and Hunsley (15)
concluded that, contrary to the GMS used in our
study, most of these instruments lack sufficient
psychometric evidence to warrant their use with
older adults. Moreover, in contrast to those
questionnaires documenting anxiety symptoms,
the GMS-AGECAT we have used has been shown
to detect in the community the ‘cases’ considered
to requery clinical intervention (31, 32). De Bruijn
et al. did use DSM-IV criteria to assess anxiety
(10), but reported that neither anxiety disorder nor
anxiety symptoms were associated with an
increased risk of dementia. Nonetheless, they did
not control for the competing risk of death and
considered that the ‘generalizability of results to
other populations was limited’ because of the
special characteristics of their sample.
Table 2. Incident cases and incidence rates of overall dementia according to anxiety status at baseline
Cases, n (%) Person-years Incidence Rate (95% CI) IRR (95%CI)* P
Anxiety status at baseline
Non-cases (n = 2321) 67 (2.9%) 9199.96 7.28 (5.73–9.25)
Subcases (n = 1645) 64 (3.9%) 6467.61 9.90 (7.75–12.64) 1.36 (0.96–1.91) 0.079
Cases (n = 91) 7 (7.7%) 346.47 20.20 (9.63–42.38) 2.77 (1.27–6.04) 0.010
CI, Confidence Interval; IRR, Incidence Rate Ratio; ZARADEMP, Zaragoza Dementia and Depression Project (at 4.5-year follow-up). Bold entries indicate statistically significant
values.
*Reported IRR of general dementia are related to non-case of anxiety; 95% confidence intervals are shown for both incidence rate and IRR; P values related to IRR were from
the z test.
Fig. 2. Probability of incident dementia by anxiety status at
baseline in the study sample.
6
Santabarbara et al.
It might be argued that the association found
between anxiety and incident cases of dementia is
the effect of preclinical disease (i.e., reverse
causation) or prodromal changes rather than a risk
factor for dementia (14, 44). Nevertheless, our
findings support the notion of increased risk,
because contrary to studies such as de Bruijn et al.
(10), Petkus et al. (11), and Acosta et al. (13), we
excluded at baseline all subcases of dementia
(AGECAT criteria) to minimize the possibility of
including in the cohort individuals with mild cog-
nitive deficits. Moreover, only cases of anxiety and
not subcases in our study were associated with
incident dementia. If anxiety was prodromic (45),
it would be expected that anxiety subcases would
also develop dementia in a 4.5-year period.
Additionally, in trying to infer causation, we
considered that at least some of the anxiety might
relate to early perceived memory difficulties.
Therefore, in a post hoc analysis we introduced in
the multivariate models the question of subjective
memory impairment (GMS criteria), but the results
were not substantially altered (anxiety case,
SHR = 2.45, P = 0.045; anxiety subcase, SHR = 1.
26, non-signifcant).
Several hypotheses may explain the increased risk
of dementia associated with anxiety disorder. First,
anxiety might promote negative neuroplasticity, as
suggested by Vance et al. (46), therefore decreasing
‘cognitive reserve’. Second, anxiety may induce an
accelerated aging across multiple biological
processes, as suggested in a recent review (47).
Third, there is growing evidence in the literature for
the role of central nervous system inflammation in
the pathology of the most common dementia in the
community, Alzheimer Disease (48), and inflamma-
tory changes have also been shown to be associated
with anxiety (49). Therefore, the possibility that
these inflammatory changes negatively influence the
pathologic processes of Alzheimer Disease should
also be considered.
Our study has other strengths, such as the use of
a representative population sample, including
institutionalized individuals (50). Moreover, we
have used instruments validated within the study.
The agreement between psychiatrists and AGECAT
in making diagnostic decisions was high in several
studies and different populations (22, 51) and, we
controlled for depression, in view of its frequent
association with anxiety in the community (52).
Some limitations must be noted, such as the
significant attrition from sampling to enrollment.
However, the attrition rate was expected by design
(17) and we previously argued that our investiga-
tion is comparable to several other two-stage
epidemiologic studies (17). While we previously
documented that the screening method used to
detect dementia is particularly sensitive in this
population (20), some ‘true’ cases may have been
missed. Because we do not know if the association
between anxiety and subsequent discovery of cases
is the same for these persons as the association of
anxiety with true incident dementia, this limitation
is unavoidable. Moreover, the agreement on
diagnosis of dementia between panel assessment
and hospital diagnosis for cases was satisfactory,
but we have no data on agreement for non-cases.
It is also apparent that some individuals with
incident dementia may have died before they could
be examined at follow-up, and therefore we do not
know their anxiety status at baseline. In view of
reports documenting an increased mortality among
the elderly with anxiety (53), it might be expected
that death would preclude the development of
dementia in a higher proportion of the anxiety
cases than in the non-cases. Had this not
happened, there would be more incident cases of
dementia among the anxiety cases. In such
circumstances, the conclusions of this study would
be reinforced. Lastly, this study, similar to the
studies reviewed in this report, did not control for
the use of benzodiazepines, antidepressants, or
other psychotropic medications, which some stud-
ies have associated with a higher risk of dementia
(54–56).
In conclusion, clinically significant anxiety
increased the risk of dementia in these study sub-
jects, even when considering mortality in the com-
peting risks model and including depression among
the confounding factors to control. These findings
may stimulate additional studies of the effect of
treating anxiety to decrease the risk of dementia.
Table 3. Risk of overall dementia for Fine and Gray models according to anxiety
status at baseline
Gender-adjusted model Multivariate model
SHR (95% CI)* P SHR (95% CI)* P
Anxiety status at baseline
Non-cases 1 – 1 –
Subcases 1.21 (0.86–1.70) 0.270 1.32 (0.91–1.89) 0.140
Cases 2.51 (1.16–5.45) 0.020 2.74 (1.18–6.35) 0.019
SHR, Subdistribution Hazard ratio. Bold entries mean the SHR is statistically
significant.
*Reported SHR of dementia is related to non-cases, CIs and P values related to
SHR were from “normal approximation” of Wald v2 test with 1 df. Gender-adjusted
Model included anxiety status and sex. Multivariate Model included terms for gen-
der-adjusted model plus sociodemographic characteristics (educational level, marital
status and living alone), medical risk factors (vascular disease, hypertension and
diabetes), health status, depression and cognitive status at baseline (MMSE score).
Both models used age as time-scale.
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